相关实验视频

Updated: May 5, 2026

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

穿皮冠状动脉干预与慢性全闭症患者的最佳医疗疗法:元分析

Sascha Macherey-Meyer¹, Khalid Salem², Sebastian Heyne¹

¹Clinic III for Internal Medicine, Faculty of Medicine, University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937 Cologne, Germany.

Journal of clinical medicine

|May 25, 2024

概括

经皮冠状动脉干预 (PCI) 治疗慢性全闭症 (CTO) 与最佳医学治疗 (OMT) 相比,显著减少心脏不良事件. 这一元分析证实了PCI.

科学领域:

心脏病学心脏病学
干预心脏病学干预心脏病学
公共卫生公共卫生

背景情况:

慢性全塞 (CTO) 在冠状动脉疾病中很常见,与较高的死亡率有关.
关于皮肤穿冠状动脉干预 (PCI) 与CTO最佳医疗疗 (OMT) 的先前研究产生了有争议的结果.
新出现的证据需要进行全面的元分析,以澄清治疗疗效.

研究的目的:

评估PCI与OMT相比在管理CTO方面的有效性.
综合最近研究的数据,提供对CTO治疗结果的最新见解.

主要方法:

一个系统的文献搜索确定了相关的随机对照试验 (RCT) 和非随机研究.
主要终点是心脏死亡率,心肌梗塞和目标血管再血管化的复合结果.
分析了32项涉及11,260名患者的研究的数据.

主要成果:

PCI与主要复合结局的显著减少有关 (OR 0.66;95% CI 0.50-0.88;p=0.005).
这种益处在所有研究设计中都是一致的,包括RCT (OR 0.58;95% CI 0.33-0.99;p=0.05).
观察到的优势主要是由目标血管再血管化驱动的,尽管死亡率和心肌梗塞也显示出显著的减少.

结论:

与OMT相比,CTO的PCI改善了以患者为导向的结果.
这些发现表明,无论研究设计如何,死亡率和心肌梗塞都显著降低.
需要进一步的大规模RCT来证实这些产生假设的结果.

关键词:

首席技术官 (CTO) 负责这些事情.急性冠状动脉综合征急性冠状动脉综合征慢性冠状动脉综合征慢性冠状动脉综合征慢性完全封闭症慢性完全封闭症最佳的医学疗法最佳的医学疗法.通过皮肤进行冠状动脉干预.

更多相关视频

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Author Spotlight: Enhancing Coronary Artery Revascularization

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

相关概念视频

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Acute Coronary Syndrome III: Diagnostic Studies

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...